Electroporation

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

Retrieved on: 
Thursday, February 29, 2024
Health, Medical Devices, Health Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Acquisition, Cancer, Regenerative medicine, Multimedia, Stemcell Technologies, Cell, Electroporation, Interim, Patient, Electricity, Intellectual property, SQZ, Research, Transfection, Fine chemical

This transaction, which was approved by SQZ shareholders on February 29, 2024, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.

Key Points: 
  • This transaction, which was approved by SQZ shareholders on February 29, 2024, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.
  • (Photo: Business Wire)
    This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.
  • In January 2024, STEMCELL purchased Propagenix Inc. , a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
  • With this new agreement, STEMCELL will be able to exclusively commercialize these products for use in all markets, including clinical applications.

Green Science Alliance Developed Dissolvable Biodegradable Micro Needle with Human Body Friendly Natural Materials

Retrieved on: 
Tuesday, January 30, 2024
Titanium, Silicon, Patient, DDS, Attention, Needle, Electroporation, Medicine, PLGA, Risk, Pain, Skin, Carbon, Hyaluronic acid, Gelatin, Drug, PGA, PLA, Protein, Sonophoresis, Collagen, Vaccine

This time, they have developed dissolvable biodegradable micro needle with human body friendly natural materials.

Key Points: 
  • This time, they have developed dissolvable biodegradable micro needle with human body friendly natural materials.
  • In this circumstances, Mr. Hirohisa Iwabayashi and Dr. Ryohei Mori at Green Science Alliance have developed biodegradable micro needle with polysaccharide which is safe and dissoluble in the human body.
  • When natural biodegradable micro needle patch is attached to the skin, drugs and active ingredients can be introduced into human body by dissolving biodegradable micro needle under the skin.
  • As such, dissolvable biodegradable micro needle has more advantages compared to conventional injection needle and can be applied to not only medical usages but also for cosmetic application.

Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers

Retrieved on: 
Monday, September 18, 2023
Other Manufacturing, Research, Genetics, Clinical Trials, Stem Cells, Manufacturing, Other Health, Biotechnology, Health, Science, GMP, DNA, Electroporation, Drug Master File, QC, PAM, Integrated DNA Technologies, RNP, Multimedia, RNA, Transfection, Chemistry, IDT, Protein, Documentation, RUO, CGMP, DMF, Integration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Fine chemical, Dietary supplement, Vaccine, CRISPR

Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.

Key Points: 
  • Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.
  • SpCas9 Nuclease—a wildtype SpCas9 nuclease for use in development work as well as standard cGMP products for clinical studies.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, DNA, Auckland City Hospital, Electroporation, Radiation, Circulating tumor DNA, University, PPM, Chief Justice of Hungary, Aes, Liquid biopsy, Cancer, Hope, Medicine, Doctor of Philosophy, Șaeș, MRD, NeXT, MRI, CD8, Patient, Sorafenib, EP, Immune system, CR, Cancer vaccine, Liver, CRS, Neoplasm, HCC, CMR, PD-1, Oncology, Pembrolizumab, Recurrence, SD, PR, Safety, Biopsy, Pharmaceutical industry, Medical imaging, Geneo Grissom

PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose liver and lung lesions shrank to become fully responsive to surgery and radiation (secondary resectability).

Key Points: 
  • Geneos reports today that four additional patients have achieved a complete molecular response (CMR) by ultrasensitive, third-generation, circulating tumor DNA (ctDNA) analysis.
  • By RECIST1.1, three of these four patients are durable partial responses (PR) and one a durable stable disease (SD).
  • By either RECIST1.1 or by ctDNA response, 11 of 32 evaluable have achieved either a complete response, partial response, or complete molecular response.
  • Cancer vaccines based on our DNA vaccine platform are showing complete responses in patients with late-stage, advanced cancer.

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Retrieved on: 
Thursday, August 10, 2023
SAB, Electroporation, Brain, University, Neoplasm, ZEUS robotic surgical system, Spine, Cryotherapy, Research, Sorbonne University, Doctor of Philosophy, Pain, MRI, Interventional radiology, MD, Faculty, Neuro, Robotics, University of Bordeaux, Medical imaging, Radiology

Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.

Key Points: 
  • Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.
  • Professor Cornelis received his MD in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France.
  • “The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company.
  • Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

Novel gene delivery technology published and licensed exclusively to Cellinfinity Bio

Retrieved on: 
Monday, July 10, 2023
Oncology, Health, Genetics, Research, Science, Biotechnology, Nature Biomedical Engineering, CRISPR, Electroporation, AAV, Messenger, Associate, Cell, Monocyte, CD8, MAJESTIC, CD4, Gene, Genome, Vaccine, Yale University

This technology is published in Nature Biomedical Engineering on July 10.

Key Points: 
  • This technology is published in Nature Biomedical Engineering on July 10.
  • Cellinfinity Bio has an exclusive license of the published MAJESTIC technology from Yale University and Professor Sidi Chen’s lab, Founder of Cellinfinity Bio and Associate Professor of Genetics, Yale University.
  • “We intend to employ MAJESTIC in multiple cell types, allowing development of next generation cell therapy against broad ailments.” Cellinfinity holds exclusive rights to the MAJESTIC technology.
  • In addition, the company has licensed other novel cell evolution technologies from Yale, that allow whole-genome gain-of-function and loss-of-function gene screens from the Chen lab.

Indee Labs Announces Exclusive Distribution Deal for With Sunko Instruments in China

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Electroporation, Partnership, Labs, Marketing, Fine chemical, Indee Gold Mine

BERKELEY, Calif., May 25, 2023 /PRNewswire/ -- Indee Labs is a biotechnology company developing the Hydropore™ for non-viral intracellular delivery. Sunko Instruments is a professional distributor of scientific and laboratory instruments in China.

Key Points: 
  • Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore Research Use Only.
  • Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore.
  • As part of the partnership, Indee Lab provides Sunko Instruments with exclusive marketing and distribution rights in China for Hydropore RUO.
  • We are excited to expand Hydropore's reach to China with an exclusive marketing and distribution agreement with Sunko Instruments."

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

Retrieved on: 
Tuesday, May 16, 2023
Apoptosis, Communication, US Foods, Electroporation, Disease, SWOG, IST, Cancer, Type, PCR, Melanoma, Patient, Collection, SAN, PMR, Immune system, Clutch (eggs), EFS, Merck, FDA, Pembrolizumab, Food, Nivolumab, Pharmaceutical industry

The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO™-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting.

Key Points: 
  • The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO™-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting.
  • In the randomized stage, neoadjuvant treatment with TAVO™-EP in combination with pembrolizumab will be compared to pembrolizumab alone.
  • The rationale for the proposed trial is an evolving standard of care in neoadjuvant melanoma treatment.
  • The Company appreciates the productive meeting with the FDA and the agency's feedback on the trial design and potential strategies for future registrational paths.

Global Transfection Technologies Market Report 2023: Sector is Expected to Reach $1,747 Million by 2028 at a CAGR of 8.35% - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 11, 2023
Health, Biotechnology, DNA, Electroporation, Prevalence, Cancer, Research, Gene expression, Cell, RNA, Government, RNA interference, Protein, Investment, Growth, R, Vivo, Oligonucleotide, Virus, Vaccine, Transfection

It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell.

Key Points: 
  • It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell.
  • It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection.
  • The publisher provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2023-2028.
  • Our report has categorized the market based on product type, application, transfection method, technology and end-user.

Endogenex™ Announces Presentation of First Human Clinical Experience

Retrieved on: 
Thursday, May 4, 2023
Mayo Clinic, Type 2 diabetes, DDW, Electroporation, Medical device, Patient

MINNEAPOLIS, May 4, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, announced presentations of early clinical experience using its ReCET™ System in three oral presentations at Digestive Disease Week (DDW) from May 6 – 9, 2023 in Chicago, IL.

Key Points: 
  • MINNEAPOLIS, May 4, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, announced presentations of early clinical experience using its ReCET™ System in three oral presentations at Digestive Disease Week (DDW) from May 6 – 9, 2023 in Chicago, IL.
  • Busch from Amsterdam University Medical Center, Amsterdam, Netherlands.
  • "We are excited to share the first clinical experience for the ReCET System with the scientific and medical community at this year's Digestive Disease Week" said Stacey Pugh, Endogenex CEO.
  • "We have collaborated with top tier institutions globally to evaluate the ReCET Therapy in the REGENT-1 and EMINENT studies and are pleased to share these initial outcomes with the broader clinical community."